Understanding Insider Buying
Investors can gain valuable insights by observing insider buying activity, as it often signals confidence in a company’s future performance. While insiders may have various reasons to sell shares, purchasing them with their own money typically indicates a positive outlook.
Chief Financial Officer Ankur Dhingra of Summit Therapeutics demonstrated confidence in the company by acquiring 100,000 shares of SMMT at $3.75 each, amounting to a $375,000 investment. Subsequently, with the stock trading at $4.64, Dhingra is already enjoying nearly a 24% return. Notably, this is not Dhingra’s first purchase, having bought $44,254 shares at $2.17 previously, within the last year.
Insider Buying Activity in SMMT
Summit Therapeutics is currently trading up by 13.1% for the day, following Dhingra’s recent purchase. This positive momentum suggests a potentially lucrative investment opportunity in the eyes of insiders.
On the other hand, Epsilon Energy saw significant insider activity, with Chief Executive Officer Jason Stabell purchasing 36,466 shares of EPSN at $5.25 each, totaling $191,446. Stabell’s repeated purchases amounting to $1.6 million over five instances in the past year, at an average price of $4.92 per share, further underscore his confidence in the company’s prospects.
Insider Buying Impact on EPSN
Epsilon Energy observed a 2.3% increase in trading on Thursday, likely buoyed by Stabell’s recent purchase. This buying spree highlights strong insider belief in the company’s potential growth and profitability.
These insider buying trends serve as a valuable barometer for investors, indicating a positive outlook from those closest to the operations and performance of these companies. Such actions instill confidence in the market and suggest a favorable trajectory for both Summit Therapeutics and Epsilon Energy.
VIDEO: Thursday 3/28 Insider Buying Report: SMMT, EPSN
Author’s viewpoint: The insights shared here are solely the author’s and may not align with Nasdaq, Inc.’s stance.